INCYTE CORP 2025 Annual Review

Incyte Corp. achieved a strong performance in 2025, reinforcing its standing as a growing biopharmaceutical leader. The company saw significant revenue growth, made strategic acquisitions, successfully launched new products, and continued investing heavily in its research pipeline.

---

Business Overview: Incyte Corp. discovers, develops, and sells its own innovative medicines. The company focuses on critical unmet medical needs, mainly in cancer, inflammation, and autoimmune diseases, through its cutting-edge research. Incyte's strategy combines developing treatments internally with forming strategic partnerships and making acquisitions to grow its portfolio of new drugs.

---

Management Discussion & Analysis (MD&A) Highlights: This section analyzes Incyte's financial health and operating results. We highlight key trends, significant events, and management's view on the company's performance and strategic direction.

Financial Performance Highlights:

Incyte's financial performance in 2025 showed significant growth. The company reported total revenue of $5.48 billion, a 16.8% increase from $4.69 billion in 2024. This growth accelerated from the 8.3% increase observed between 2023 and 2024, demonstrating strong momentum.

• Profitability: Incyte's Net Income reached $800 million in 2025, up from $700 million in 2024. This resulted in Diluted Earnings Per Share (EPS) of $3.64 in 2025, an increase from $3.18 in 2024, showing improved profitability per share.
• Cash Flow: Incyte generated $1.2 billion in cash flow from operations in 2025, reflecting strong operational efficiency. After capital expenditures, Free Cash Flow totaled $900 million, providing significant financial flexibility for future investments and shareholder returns.

Key Product Performance & Growth Drivers:

Strong sales from key products and increased royalty income primarily drove Incyte's revenue growth:

• JAKAFIM: Our flagship product, JAKAFIM, continued its strong performance, generating $2.6 billion in sales in 2025, a modest increase from $2.5 billion in 2024. JAKAFIM remains a core revenue driver, primarily treating myelofibrosis, polycythemia vera, and graft-versus-host disease.
• OPZELURA: OPZELURA became a significant growth driver, with sales surging to $400 million in 2025. This represents a remarkable 33% jump from $300 million in 2024, continuing its rapid growth from $200 million in 2023. OPZELURA treats atopic dermatitis and non-segmental vitiligo.
• New Product Launches: Incyte successfully launched two new products in 2025, NIKTIMVO and ZYNYZ. Each contributed $10 million in initial sales, showcasing the company's ability to bring new therapies to market and diversify revenue.
• Royalty Income: Royalty revenues from partners also grew steadily. Incyte received $1.4 billion from Novartis for JAKAVI (the ex-U.S. brand of ruxolitinib) and $150 million from Eli Lilly for Olumiant, reflecting the value of Incyte's intellectual property and development expertise.

Operating Expenses:

As a biopharmaceutical company, Incyte continues to invest significantly in its future:

• Research and Development (R&D): R&D expenses rose to $1.9 billion in 2025 from $1.8 billion in 2024. This increase highlights Incyte's commitment to discovering and developing new medicines and is crucial for replenishing its product pipeline.
• Selling, General & Administrative (SG&A): SG&A costs increased to $1.4 billion in 2025 from $1.3 billion in 2024. This was primarily due to increased commercialization efforts for new product launches and expanded sales and marketing activities for existing therapies.
• Cost of Sales: Direct costs for producing and selling Incyte's drugs increased to $400 million in 2025 from $300 million in 2024, aligning with higher product sales volume.

---

Financial Health: Incyte maintained a healthy financial position, ending 2025 with $1.5 billion in cash and cash equivalents. Total debt remained manageable at $1.0 billion, supported by a $500 million revolving credit facility available until August 2026, which ensures ample liquidity. Shareholder equity grew to $10 billion in 2025 from $9 billion in 2024, reflecting growth in assets funded by retained earnings. This strong balance sheet provides financial flexibility for strategic investments and operational needs.

---

Competitive Position: Incyte operates in highly competitive therapeutic areas, primarily cancer, inflammation, and autoimmune diseases. Our competitive edge comes from our focus on innovation, the strength of our proprietary product portfolio (including market leaders like JAKAFIM and rapidly growing OPZELURA), and our robust research and development pipeline. We compete on factors such as product effectiveness, safety, intellectual property protection, speed to market, and commercial execution. Strategic acquisitions and partnerships further strengthen our ability to compete by expanding our therapeutic reach and pipeline assets.

---

Strategic Developments & Competitive Positioning:

Incyte made several strategic moves to strengthen its pipeline and market presence:

• Key Acquisitions: In February 2024, Incyte acquired MorphoSys AG, significantly expanding our cancer pipeline, especially in hematology. We then acquired Escient Pharmaceuticals in May 2024 for $750 million, adding promising early-stage assets like INCB000262 and INCB000547, which target inflammatory and autoimmune diseases. These acquisitions are central to our strategy of inorganic growth and pipeline diversification.
• Share Repurchase Program: We demonstrated confidence in our valuation and commitment to shareholder returns by announcing a share repurchase program in May 2024. This included a "Dutch Auction" tender offer to buy back between $1.0 billion and $1.2 billion of our own stock.
• Pipeline & Partnerships: Beyond acquisitions, Incyte continues to advance its internal pipeline and leverage strategic partnerships, such as those for Axatilimab with Syndax. These collaborations help us bring forward new therapies across cancer, inflammation, and autoimmune disorders. This multi-pronged approach strengthens our competitive position in specialized therapeutic areas.

---

Key Risks & Challenges:

While Incyte delivered strong performance, investors should be aware of several key risks:

• Customer Concentration: A few large customers account for a significant portion of Incyte's revenue. In 2025, our top customer generated 27.4% ($1.5 billion) of total revenue, and the top three customers collectively represented over 56%. This reliance creates vulnerability if these customer relationships deteriorate or if they face financial difficulties. Similarly, a large portion of our accounts receivable is concentrated with key partners like Novartis and Eli Lilly.
• Product Dependence: A few key products, primarily JAKAFIM and OPZELURA, generate a substantial portion of Incyte's revenue. Adverse events, new competitors, patent expirations, or regulatory challenges affecting these products could significantly impact our financial performance.
• R&D Success & Clinical Trial Risk: Despite significant R&D investment, we cannot guarantee that pipeline candidates will successfully complete clinical trials, gain regulatory approval, or achieve commercial success. Clinical trial failures or unexpected safety concerns could lead to substantial financial losses and impact future growth.
• Regulatory & Pricing Pressures: As a biopharmaceutical company, Incyte operates in a highly regulated environment. Changes in FDA approval processes, drug pricing policies (such as potential impacts from the Inflation Reduction Act), or increased scrutiny from healthcare payers could negatively affect our profitability and market access.
• Competition: The biopharmaceutical industry is intensely competitive. Incyte faces competition from established pharmaceutical companies and emerging biotech firms. This could lead to pricing pressure, market share erosion, or the need for increased R&D spending to maintain a competitive edge.
• Patent Expiry: The eventual expiration of patents for key products like JAKAFIM could lead to generic competition, significantly reducing sales and profitability.

---

Future Outlook: Incyte is strategically positioned for continued growth, driven by its expanding product portfolio, robust pipeline, and strategic acquisitions. The successful launch of NIKTIMVO and ZYNYZ, combined with the strong performance of JAKAFIM and OPZELURA, provides a solid foundation. We expect the acquisitions of MorphoSys AG and Escient Pharmaceuticals to generate future revenue and diversify our therapeutic focus, especially in cancer and inflammation. Our ongoing substantial investment in R&D, healthy cash position, and commitment to shareholder returns through share repurchases underscore a proactive strategy for sustained long-term value creation. Incyte's focus on innovation and strategic expansion aims to navigate the evolving market trends and regulatory landscape within the biopharmaceutical industry.